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The disturbance of apoptosis molecular signaling pathways is involved in carcinogenesis. BCL2 family of proteins is the hallmark
of apoptosis regulation. In the last decade, new members of BCL2 gene family were discovered and cloned and were found to
be diﬀerentially expressed in many types of cancer. BCL2 protein family, through its role in regulation of apoptotic pathways,
is possibly related to cancer pathophysiology and resistance to conventional chemotherapy. It is well known that leukemias are
haematopoietic malignancies characterized by biological diversity, varied cytogenetics, diﬀerent immunophenotype proﬁles, and
diverse outcome. Current research focuses on the prognostic impact and speciﬁc role of these proteins in the pathogenesis of
leukemias. The understanding of the molecular pathways that participate in the biology of leukemias may lead to the design of
new therapies which may improve patients’ survival. In the present paper, we describe current knowledge on the role of BCL2
apoptosis regulator proteins in acute and chronic leukemias.
1.Introduction
Apoptosis, or programmed cell death, is a cell-suicide pro-
gram, distinct from necrosis, which isactivated in physiolog-
ical processes such as tissue development and diﬀerentiation
as well as in pathophysiological conditions. The term is used
to describe the situation in which a cell actively pursues
a course toward death upon receiving certain stimuli. The
morphological changes of apoptosis found in most cell
types include nuclear pyknosis, DNA fragmentation and
chromatin condensation, cytoskeleton destruction, mem-
brane blebbing, and eventually the formation of membrane
apoptotic bodies, which are phagocytosed by macrophages
and other cells without promoting inﬂammatory response
[1]. The mechanism of apoptosis is evolutionarily con-
servedandisexecutedbyafamily ofproteins,calledcaspases.
Caspases are cysteine proteases that are cleaved after an Asp
residue in their substrates. They are synthesized as latent
zymogenes and activated by proteolytic cleavage; their ac-
tivation is mainly regulated by the BCL2 family proteins
[2–4].
BCL2 gene (otherwise B-cell lymphoma 2 gene, bcl-2)
was ﬁrst discovered in follicular B-cell lymphoma as a gene
which is linked to the immunoglobulin heavy chain locus at
thebreakpointsoft(14;18)translocation[5];theresultofthis
translocation is the enhanced BCL2 protein transcription. In
normal cells this gene is located on chromosome segment
18q21.3. BCL2 protein was found to inhibit cell death. This
discovery was a revolution in the way of approaching cancer
pathology, since it gave birth to the notion that tumor
genesis could be due to not only unlimited proliferation, but
also to impaired apoptosis. It should be noticed that BCL22 Advances in Hematology
oncoprotein overexpression is found not only in follicular
non-Hodgkin’s lymphoma but also in other haematopoietic
malignancies and solid tumors, independent of t(14;18)
chromosomal translocation.
There are two known distinct pathways which lead to
apoptosis (Figure 1). The ﬁrst, which is called the intrinsic
cell death pathway, is evoked by intracellular stresses like
radiation, growth factor withdrawal, cytokine deprivation,
cytotoxic drugs and is regulated by BCL2 family proteins
[6, 7]. Progression through this pathway leads to the release
of cytochrome c from the damaged mitochondrion, which
then binds to the adaptor molecule APAF-1 and an inac-
tive “initiator” caspase, procaspase 9, within a multiprotein
complex called the apoptosome. This leads to the activa-
tion of caspase 9, which then triggers a cascade of caspases
activation (caspases 3 and 7) resulting in the morphologi-
cal and biochemical changes associated with apoptosis. The
second cell death pathway is the extrinsic pathway, which
functions independently of mitochondria. This pathway is
activated by the cell-surface death receptors CD95 (Apo-1 or
Fas)/TRAIL/tumor necrosis factor (TNF) receptor 1 family
proteins which are located on the plasma membrane, and
directly activates the caspase cascade via the recruitment of
the “initiator” caspase-8 within a death-inducing signaling
complex (DISC) [8].
Impaired apoptosis is a hallmark of the pathogenesis of
many forms of cancer [9–16]. This paper focuses on the role
of BCL2 family members in the biology, progression, prog-
nosis, and therapy of acute and chronic leukemias.
2.BCL2FamilyofApoptosisRegulatorProteins
Mammalian BCL2 protein family consists of at least 30 re-
lated proteins, characterized by the presence of up to four
relatively short sequence motifs (less than 20 amino acid
residues in length) termed BCL2 homology (BH) domains
[17–21]. BCL2 family is divided into three diﬀerent sub-
classes based on structural and functional features.
2.1. Prosurvival or Antiapoptotic Family Members. The pro-
survival or antiapoptotic subfamily includes BCL2, BCL-XL,
BCL-W, and MCL-1 proteins, which possess all four con-
served BH domains, designated BH1-4, and a hydrophobic
C terminal part. BH1-BH3 domains form a hydrophobic
groove and the N-terminal BH4 domain stabilizes this struc-
ture. BH4domain is usually absent in apoptoticproteins and
therefore is a key factor for the antiapoptotic activity. The
B H 4d o m a i no fB C L 2c o n s i s t so f2 6a m i n oa c i d sa n di t s
structure shows an amphipathic character upon interaction
with the membranes, akin to antimicrobial peptides. The β-
sheet conformation of BH4 in water is concerted into an
a-helical structure, appropriate to interact favorably with
the negatively charged membranes [22]. It appears that the
proteins are mainly located outside the membrane, however
their exact insertion and complex formation is not well
understood. BCL2 is permanently found in membranes,
whereas BCL-XL and BCL-W are linked to the membrane
after a cytotoxic signal [6].
BCL2 (and its antiapoptotic orthologues) seems to in-
hibit apoptosis by the preservation of mitochondrial mem-
brane integrity as its hydrophobic carboxyl-terminal domain
is linked to the outer membrane. BCL2 prevents BAX/BAK
oligomerization, which would otherwise lead to the release
of several apoptogenic molecules from the mitochondrion.
It is also known that BCL2 binds to and inactivates BAX and
other pro-apoptotic proteins, thereby inhibiting apoptosis.
BCL2 might also regulate the activation of several initiator
caspases likecaspase-2 that act upstream or independentlyof
cytochrome c release from mitochondria. Moreover, BCL2
directly blocks cytochrome c release and therefore prevents
APAF-1 and caspase-9 activation.
BCL2 has not only been localized to the outer mitochon-
drial membrane but also to the nuclear envelope and the
endoplasticreticulummembrane(ER).IntheER,itregulates
calcium storage, whose intracellular levels have been shown
to aﬀect apoptosis. ER-associated BCL2 is able to protect
from apoptosis induced by various triggers. Beyond BCL2,
BCL-XL also interacts with pro-apoptotic members like
BAX and BAK thought their BH3 domains [22, 23]. It is
possible that the antiapoptotic action of BCL2 and BCL-XL
is converted to a pro-apoptotic one when these proteins are
cleaved by caspases after initiation of apoptosis [24].
MCL-1proteinhasashorthalf-life (estimatedatlessthan
1h) which is unique among antiapoptotic BCL-2 family
members. Underbasal conditions,human MCL-1 undergoes
rapid protein turnover, but the control of this constitutive
degradation pathway is incompletely understood. MCL-1
can be cleaved by caspases and granzyme B, which pro-
teolytically degrade MCL-1 during cell death. In addition,
h u m a nM C L - 1c a nb eu b i q u i t i n y l a t e da n dd e g r a d e db yt h e
proteasome. Several levels of degradation control have been
postulated.ThetightregulationofMCL-1proteinexpression
makes it an ideal regulator of cell survival. In response to cel-
lular signaling, MCL-1 protein levels can be rapidly induced
by inducing new MCL-1 transcription and by preventing
MCL-1 protein turnover. When cells need to be eliminated,
MCL-1 levels can be rapidly diminished by blocking new
protein synthesis and degrading the existing MCL-1. Dys-
regulation of this balance, by inappropriately promoting
its synthesis or by blocking its elimination, can lead to
inappropriate stabilization of MCL-1 and promote cellular
survival. Furthermore, dysregulated MCL-1 levels can lead
t oi n a p p r o p r i a t ec e l ls u r v i v a lo rd e a t h ;t h e r e f o r e ,u n d e r -
standing regulation of MCL-1 levels is of great importance
[25–27].
2.2. Proapoptotic Family Members. The pro-apoptotic mem-
bers such as BAX, BAK, and BOK usually share sequence
similarity inBH1,BH2,BH3butnotinBH4domain[17,28–
30]. BAX protein is a monomeric protein in the cytosol,
which integrates into the mitochondria during apoptosis
and subsequently oligomerizes, resulting to the release of
apoptogenic factors like cytochrome c and the activation of
the caspase cascade. On the other hand, BAK is an integral
mitochondrial membrane protein, which also undergoes
conformational changes to form larger aggregates during
apoptosis [29]. BAX and BAK are also present in the ER,Advances in Hematology 3
Extrinsic pathway
DISC
FADD
Caspase-8
Caspase-9
Caspase-3
Intrinsic pathway
BCL2
BID BAX
Omi-diablo
BCL XL
Apoptosis
Mitochondrion
IAP
APAF-1+cytochromec
TNF-α, TRAIL, FAS
Figure 1: In this ﬁgure we show the two main pathways to apoptosis, and their interaction through the molecule BID, since death receptors
activate the intrinsicpathway by activating BID. Either BAX or BAK are required for apoptosis,where they oligomerizein the mitochondrial
outer membrane and induce the release of cytochrome c. DISC: death-inducing signaling complex, FADD: FAS-associated protein with
death domain, TRAIL: TNF-related apoptosis-inducing ligand, APAF-1: apoptotic protease-activating factor, IAP: inhibitor of apoptosis
proteins.
where they control apoptosis through the regulation of cal-
cium levels [31]. The localization of BCL2 to the ER me-
mbrane supports the concept that it regulates ER-located
BAX and BAK function. P53 can activate BAX, which lacks a
clearly identiﬁable BH3 domain [32]. During drug-induced
apoptosis BAX is cleaved by caspases and activated calpains
[33].
2.3. BH3-Only Family Members. BH3-only proteins include
a number of the proapoptotic proteins such as BID, BIM,
BIK, BAD, BMF, HRK, DIVA, NOXA, and PUMA. These
share sequence similarity only in the BH3 domain. They
are activated by diﬀerent mechanisms, among which are
transcriptional upregulation, proteolytic truncation, and
phosphorylation. BIM and BMF are released upon phos-
phorylation, whereas BAD is released upon dephospho-
rylation [34]. BAD molecule is also cleaved by caspases
w h e na p o p t o s i si si n d u c e db yt r a n s f o r m i n gg r o w t hf a c -
tor β1[ 35]. BID is unique among the BH3-only BCL2
family members in interconnecting death receptors to the
mitochondrial ampliﬁcation loop of the intrinsic pathway.
The potent proapoptotic activity and broad expression
patterns of BID require that cells carefully regulate its
apoptotic activation. Subcellular localization appears to
play a role in directing the proapoptotic activity of BID.
Following death receptor stimulation, BID is activated by
caspase-8 cleavageand N-myristoylation totargetmitochon-
dria, where it activates BAX and BAK or is alternatively
sequestered by antiapoptotic BCL2 members, preventing
death. Full-length BID is also capable of translocation
t ot h em i t o c h o n d r i ai na tl e a s to n ec a s ef a c i l i t a t e db y
other proteins such as PACS2. In the mitochondria, full-
length BID has been shown to potentiate cell death fol-
lowing certain apoptotic signals, suggesting that caspase
cleavage is not an absolute requirement for activating the
proapoptotic function of BID. Recent studies indicate that
activation of prodeath activity of BID may be negatively
regulated by phosphorylation. Casein kinases have been
implicated in BID phosphorylation, and ATM has been
shown to phosphorylate BID following DNA damage [36–
39]. Moreover, BID is proteolytically cleaved by caspase-
8 and granzyme B. In acute T lymphoblastic leukemia
cells, BID was found to be proteolytically activated by
an aspartate-speciﬁc protease and to play a crucial role
in mitochondrial activation in the p53-independent DNA
damage response to etoposide and γ-radiation [40]. BH3-
only proteins have dual function: both positive and negative
regulation of BCL2 family members. Several BH3 peptides
relieved the inhibition of BAX caused by the antiapoptotic
BCL-XL and/or MCL-1 proteins and some of them display
speciﬁcity for either BCL-XL or MCL-1. BIM and BID
were the only BH3 peptides found to induce cytochrome
c release from mitochondria in vitro. They are thought to
trigger apoptosis by binding and therefore inactivating the
antiapoptotic BCL2 relatives, whereas BID seems to promote
apoptosis by activating BAX and BAK [41]. Recent studies
show that there are two diﬀerent subgroups in the BH3-
only proteins: the ﬁrst consists of BIM and BID which
induce mitochondria permeabilization via BAX and BAK
and are called death agonists. The second includes BAD and
BIK. These proteins induce mitochondria permeabilization
by opposing antiapoptotic proteins like BCL2, and they
are called survival agonists. Peptides that resemble BIM
and BID can directly activate BAD, whereas the rest BH3-
domain-like peptides act indirectly and require the presence
of BIM and/or BID that can directly activate BAD [41].
2.4. Newly Identiﬁed Proteins of the BCL2 Family Include
BCL2L10 (BOO/DIVA),BCL2L12, BCL2L13 (BCL-RAMBO),
BCL2L14 (BCL-G), and MAP-1 [9]. BCL2L10 is an anti-
apoptotic gene mapped on human chromosome 15q21.2.
It encodes for the widely expressed protein BCL2L104 Advances in Hematology
(BOO/DIVA) in adult human tissues, with its highest levels
typically found in liver, pancreas, kidneys, brain, and lungs.
BCL2L12 genemaps onchromosome 19q13.3.It encodes
for BCL2L12 protein which has a predominant molecular
mass of 36.8kDa. BCL2L12 protein contains the conserved
BH2 domain of BCL2 family and a putative BH3 domain
[9, 10]. There is evidence that BCL2L12 interacts with BCL-
XL protein. Additionally, it bears repeated PXXP motifs and
a proline rich region that is essential for the interaction with
the src homology region (SH3) of tyrosine kinases, such as
the protooncogenes c-Scr and c-Abl. It is worth mentioning
that it is the ﬁrst gene identiﬁed encoding for a protein
which contains both a proline rich and a BH2 domain.
The recent identiﬁcation of the BAX-binding protein BIF-
1 suggests a probable connecting role of BCL2L12 among
the apoptotic proteins and the SH3-bearing oncoproteins
[9, 10]. Recently, it was found that BCL2L12 neutralizes p53
signaling in glioblastoma [8]. One splicing variant missing
exon 3 and expressing a 176 amino acid truncated protein
with no BH2homologydomain has also beenidentiﬁed. The
classicformoftheBCL2L12proteinishighlyexpressedinthe
thymus,prostate,fetalliver,mammary, colon,placenta,small
intestine, kidney, and bone marrow, with lower levels being
expressed in all other tissues. The splice variant is highly
expressed in fetal liver, spinal cord, and skeletal muscle,
where it is present at higher levels than the classical form
of the gene, compared to the other tissues. BCL2L12 is also
overexpressed in many types of malignancies [9–13].
BCL2L13 widely expressed protein displays a signiﬁcant
similarity to the BCL2 family of proteins, containing all four
conserved BH domains (BH1/BH2/BH3/BH4),separated by
a 250 amino acid insertion with two tandem repeats rich
in serine residues from the characteristic hydrophobic c-
terminal membrane anchor (MA). It is characterized by
proapoptotic activity and is localized to mitochondria in
mammalian cells, although it appears that it induces apop-
tosis independently of the classical mitochondrial signaling
pathways without involving BH4 or other BH domains.
BCL2L14 is another novel human proapoptotic member
of the BCL2 protein family. The BCL2L14 gene maps on
chromosome 12p12. It consists of six exons and undergoes
alternative splicing producing three diﬀerent proteins (BCL-
Gs,B C L - G M,B C L - G L), whose overexpression in various cell
lines, such as COS-7 and HEK293T, induces apoptosis. The
largest product, BCL-GL (327 amino acids), is diﬀusely dis-
tributed in the cytosol and displays a wide tissue distribution
including bone marrow, prostate, pancreas, colon, testis,
and spleen. It possesses both BH2 and BH3 domains and
it can interact with BCL-XL, which blocks its proapoptotic
function.
MAP-1 (modulator of apoptosis-1) is another proapop-
toticBH3domain-onlyprotein.Itinteracts withBAX,BCL2,
and BCL-XL and itself to form dimers in vivo and in vitro
in mammalian cells. Its association with BAX through its
BH3 motif seems to be responsible for its caspase-dependent
proapoptoticfunction,which isevidentuponoverexpression
[9]. The better studied members of BCL2 gene family are
further presented in Table 2.
3.BCL2 GeneFamilyand ALL
A number of studies have linked impaired apoptosis and de-
regulation of BCL2 gene family with the pathogenesis and
treatment failure inALL.Arecentstudy[42]indicatedahigh
frequencyofBCL2mRNAoverexpressionandarelativelylow
frequency of BAX mRNA overexpression in ALL and AML,
suggesting that altered transcription of these genes may be
involved in leukemogenesis. Moreover, BCL2 expression in
neoplastic cells from patients with precursor B-ALL, typical
ALL and atypical ALL was found to be aberrant in 84%,
77%, and 75% of the cases, respectively, consistent with a
diverse expression of BCL2 in the diﬀerent types of ALL
according to the stage of B-cell maturation. [43]. In other
words, abnormal BCL2 gene expression seems to inﬂuence
the survival capacity of B-cell progenitors and contribute to
leukemogenesis [44]. Additionally, Aref et al. [45]s h o w e d
that the expression of BCL2 was higher in patients with
ALL as compared to controls. Although there is a higher
expression of BCL2 in ALL patients, clinical studies failed
to correlate this with survival. Sahu and Das [46]f o u n d
that there was no correlation between BCL2 expression
and overall survival. Another study by Campos et al. led
to similar results: high levels of BCL2 were not associated
with clinical or biological characteristics in adult patients
with ALL (survival of leukemic cells, outcome after intensive
chemotherapy) [47]. Although ALL patients that responded
to induction chemotherapy had lower BCL2 expression
compared to the nonresponders, no correlation between
BCL2 expression and the outcome was found.
Findings regarding lineage-dependent BCL2 expression
in ALL are controversial. According to one study, T-ALL
but not B-ALL blasts showed higher BCL2 expression in
comparison to normal subjects. This ﬁnding could explain
the poor outcome of the adult patients with T-ALL. On the
other hand, another study showed that blasts from pediatric
patients with T-ALL expressed lower BCL2 protein when
compared to patients with B-ALL [48]. Recent data from
more sophisticated techniques, such as DNA microarrays,
are also informative of the role of apoptosis genes in ALL.
The expression of apoptosis genes is diﬀerent in the subtypes
of ALL, according to lineage origin of the disease and the
cytogenetic features. As far as other clinical features are
concerned,CD10positiveB-ALLblastsproducehigherlevels
of BCL2 and there is no correlation between BAX expression
or BCL2/BAX ratio and other prognostic features of ALL
like age, gender, karyotype, or WBC count at the time of
diagnosis. Finally, lower expression of BCL2 protein among
patients with ALL is observed in patients older than 45
years old and patients with an abnormal karyotype, that
is, chromosome of Philadelphia or other translocations [49,
50].
The molecular events underlying the progression of T-
lymphoblastic lymphoma (T-LBL) to acute T-lymphoblastic
leukemia (T-ALL) remain elusive. A recent study revealed
autophagy and increased levels of BCL2, S1P1, and ICAM1
in human T-LBL compared with T-ALL. Inhibition of S1P1
signaling in T-LBL cellsledtodecreasedhomotypicadhesion
in vitro and increased tumor cell intravasation in vivo [51].Advances in Hematology 5
Table 1: This table summarizes the general ﬁndings regarding BCL2 family members in each type of leukemia.
Type of Leukemia BCL2 family members involved in disease Correlation with overall survival and outcome
ALL High levels: BCL2, BAX, MCL-1 No correlation
↑MCL-1 → resistance to chemotherapy
AML
High levels: BCL2, BCL-XL, BAD, BCL2/BAX ratio
especially in M4,M5,M6 subtypes and in CD34+
blasts
↑BCL2 and FAS → no correlation
↑BAD and BAX, ↑BCL2/BAX ratio → worse
outcome
CLL
High levels: BCL2, BCL-W, BAD, BAK, BAX,
BCL2/BAX ratio Conﬂicting results
No participation of BIK and BCL-XL
↑MCL-1, ↑BAX, ↑BAG-1 ↑BCL2 → resistance
to chemotherapy
CML High levels: MCL-1, BCL2 Low levels of BIM BCL2: key protein in disease progression
Table 2: This table summarizes the properties of the most well-studied members of BCL2 family.
Action Mechanism of action Subcellular localization
BCL2 Antiapoptotic Inhibits apoptosis by preservation of
mitochondrial membrane integrity
(i) Outer mitochondrial membrane
(ii) Nuclear envelope
(iii) Membrane of the endoplastic reticulum
(ER)
BCL-XL Antiapoptotic
Inhibits cytochrome c release through the
mitochondrial pore that inhibits activation of the
cytoplasmic caspase cascade by cytochrome c
Transmembrane molecule in the
mitochondria
BCL-W Antiapoptotic Reduced cell apoptosis under cytotoxic conditions Exclusively on the mitochondrion
MCL-1 Antiapoptotic
Short half-life, interaction with BAK1, Noxa,
BCL2L11, Bcl-2-associated death promoter,
PCNA
Mitochondria, nucleus
BAX Proapoptotic Release of apoptogenic factors like cytochrome c,
activation of caspase cascade Cytosol
BAK Proapoptotic Undergoes conformationalchanges to form larger
aggregates during apoptosis Integral mitochondrial membrane protein
BID Proapoptotic Direct activator of Bax Cytosol and membrane
BIM Proapoptotic Free Bim binds to Bcl-2 or Bcl-XL and inactivates
their antiapoptotic functions Free BIM in mitochondria
BAD Proapoptotic
Dephosphorylated BAD forms a heterodimer
with Bcl-2 and Bcl-xL, inactivating them and thus
allowing Bax/Bak-triggered apoptosis
Free BAD in mitochondria
As far as other members of the BCL2 family are
concerned, there are data concerning BAX and BCLXL that
are worth mentioning. Studies investigating the expression
of BAX protein and the probability of relapse in children
with ALL are contradictive. High levels of BAX protein have
been associated with an increased probability of relapse [48].
However, both BAX expression levels and the BAX/BCL2
ratio were, according to another study, signiﬁcantly lower in
samples at relapse compared to samples at initial diagnosis.
Moreover, at initial diagnosis ALL patients displayed spon-
taneous in vivo processing of caspase 3, whereas this was
completely absent at relapse [52]. BCLXL has been shown in
animal studiestodemonstrate anoncogenicsynergy with the
c-myc oncogene towards the development of ALL [53], and
in ALL pediatric patients it could represent an independent
prognostic factor of overall survival [54].
Furthermore, BCL2 levelsinﬂuence the sensitivity ofleu-
kemiccells totherapy [44]. Accordingto a recent study, there
is an association between lower expression levels of CASP3,
CASP8,a n dFAS gene and a poor response to induction
therapy at day 7 and prognosis in childhood ALL. The
same study indicated an association between higher levels
of BCL2 and white blood cell (WBC) count <50,000/mm3
at diagnosis and low risk group classiﬁcation [55]. The
diﬀerentialregulation ofpro-and antiapoptotic BCL2family
members appears to be a key event in the execution of
dexamethasone-induced apoptosis in ALL cell lines and
also indicates a role of these proteins in primary ALL cells
[56]. Using primary lymphoblasts from ALL children during
systemic glycocorticoidmonotherapy and related cell lines, it
was shown that a subsequent induction of the proapoptotic
BH3 molecules BMF and BIM and also an unexpected6 Advances in Hematology
signiﬁcant repression of the proapoptotic BCL2 protein
Noxa take place [57]. In addition, a study of the expres-
sion of 70 apoptosis genes in relation to lineage, genetic
subtype, cellular drug resistance, and outcome in childhood
ALL indicated that MCL1 was signiﬁcantly associated with
prednisolone sensitivity, whereas BCL2L13 was correlated
with L-asparaginase resistance and with unfavorable clinical
outcome [58].
To summarize the most important ﬁndings regarding
BCL2 gene family in ALL one should note the higher fre-
quency of BCL2 mRNA overexpression and the lower fre-
quency of BAX mRNA overexpression in ALL cases, and the
diverse expression of BCL2 in the diﬀerent types of ALL
according to the stage of B-cell maturation. However, dif-
ferent studies have failed to correlate the altered expression
of these genes with survival. Findings regarding lineage-
dependent BCL2 expression in ALL are controversial. Fur-
thermore, BCL2 levels inﬂuence the sensitivity of leukemic
cells to therapy and it has been shown that diﬀerential
regulation of pro- and antiapoptotic BCL2 family members
appears tobe a keyeventinthe executionofdexamethasone-
induced apoptosis in ALL cell lines.
4.BCL2Gene Familyand AML
BCL2 gene family is overexpressed in AML and seems to
play an important role not only in disease pathogenesis but
also in resistance to chemotherapy. The importance of BCL2
family members in AML is indicated by the expression of
BCL2,BCL2L12, BCL-XL, andBADinleukemicCD34+cells,
whereas normal promyelocytes (in non-APL AML cases)
(CD34-CD33+) lack BCL2 and BCL-XL expression. A low
BCL2/BAXratio isfound in>20% ofCD34+ cells, in M0/MI
FAB subtypes, and in those patients with poor prognosis
karyotype. Leukemic promyelocytes with the phenotype
CD34+CD33-CD13—express only BCL-XL protein and not
BCL2 [9, 59]. Moreover, the enhanced expression of BCL2 in
CD34+ cells oﬀers them a survival advantage and resistance
to chemotherapy [59]. Finally, BCL2 expression plays an
important role in maintaining a favorable antiapoptotic
microenvironment for the survival of AML blasts. In vitro
studies show that stable BCL2 protein levels reduce T-cell
apoptosis and favour the survival of peripheral blood cells
and malignant cells [60]. This microenvironment also
prevents T-cell activation and proliferation by inhibition of
several molecules like NF-κB, c-MYC, and pRB, that enables
malignant cells escape from immune surveillance [61].
BCL2 expression levels have been associated with FAB
classiﬁcation, age,and cytogeneticsof AML in several studies.
BCL2 is not expressed in M2 FAB subtype, in contrast to
M4, M5, M6 subtypes. Positive expression of BCL2 is also
foundinthemoreimmatureAMLsubtypesM0andM1[62].
Not only a higher BCL2 expression but also a lower CD95
(or FAS molecule) expression is found in immature FAB
M0/M1 AML cells compared to the more mature M2/M5
s u b t y p e s .H o w e v e r ,n om a t u r a t i o n - d e p e n d e n td i ﬀerence
in BAX expression is observed [63]. On the other hand,
Kornblau et al. [64] found no association between BCL2
expression and FAB classiﬁcation, the percentage of blasts or
cytogenetic abnormalities.
Cytogenetics is the most important predictive factor in
AML and the association of apoptosis and several gene
mutations or chromosomal abnormalities is interesting. The
prognostically favorable chromosomal translocation t(8;21),
which is commonly found in middle-aged adult AML
patients, creates the AML1/ETO fusion protein and induces
antiapoptotic BCL2 expression in vitro [65] ,b u tt h i si sn o t
conﬁrmed in vivo [66]. Additionally, high BCL2 protein
levels were detected by Western blotting in 198 patients
with AML and were considered to be an adverse prognostic
factor for patients with favorable or intermediate prognosis
cytogenetics, for example, inversion (16), t(8;21), t(15;17).
On the contrary, high BCL2 levels represent paradoxically
a favorable prognostic factor for the group of patients
with poor risk karyotype (e.g., 11q23, Ph+, deletion 5 and
7, or complex changes) [64]. Several studies indicate that
BCL2 is a prognostic factor for AML [67]. Patients with
higher BCL2 mRNA levels show lower complete remission
(CR) rates and worse outcome. There is no association
between remission rate or survival and BCL2 expression
in patients >60 years and in patients with AML following
myelodysplastic syndromes [67]. As far as other members
of the BCL2 family proteins are concerned, high levels of
BAD and BAX mRNA are associated with patient failure to
enter CR and increased BAD or BAD and BAX expression
predicted an adverse outcome regardless of the response to
induction chemotherapy. Following induction chemother-
apy, the presence of increased levels of BAX and BCL2/BAX
ratio are independent predictors of unfavorable outcome
[68]. In contrast, Ong et al. found that high BAX expression
at diagnosis is correlated with signiﬁcantly longer disease-
free survival, event-free survival, and overall survival [69].
Abnormal expression proﬁle of BCL-X gene is associated
with recurrence in AML,butno mutationin BCL-X genehas
been detected. There are two products of this gene, BCL-XL
and BCL-XS. BCL-XL transcript is found in most patients
at diagnosis and during relapse, but BCL-XS transcript is
detected in fewer cases. There is an indication that the loss
of BCL-XS expression is a prognostic factor in AML, but this
requires further investigation [70].
Correlation of BCL2family members with otherproteins
that appear to inﬂuence their levels of expression is also
interesting. Protein kinase C (PKC) phosphorylates BCL2
protein and BAX modulates BCL2 dimerization. It was
found that, in AML patients, BAX and PKCa levels are
heterogeneous, do not correlate with the percentage of blasts
in the sample, and their expression is similar among FAB
groups with a greater range for M4. Patients with inversion
16 had lower BAX levels. No correlation with prognosis
was found. Nevertheless, low BCL2/BAX and PKCaB2/BAX
ratios correlate with longer survival. Patients with unfavor-
able cytogenetics are an exception to this ﬁnding and have
the worst outcome [71].
A novel receptor tyrosine kinase, named AXL, was found
to be expressed in AML speciﬁcally of monocytic origin.
Thirty-ﬁve percent of AML patients express this kinase.
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AXL, suggesting a possible correlation between the two pro-
teins. No diﬀerencein prognosis between patientspositive or
negative for AXL expression is found, but patients with very
high levels of this protein have a dismal outcome [72].
Additionally, BCL2 expression is subjective to cytokines.
Blastsproducehighinterleukin-1(IL-1)levels,intheabsence
of exogenous growth factors. IL-1 enhances the autonomous
growth of these cells [73]. Activation of IL-1 receptor leads
to leukemic cell survival and poor outcome through three
signaling pathways. The ﬁrst is PIK3 pathway and interferes
with the BCL2 protein family: it either activates PKC and
then BCL2 via phosphorylation, or activates pAkt which
subsequently inactivates BAD through phosphorylation [74,
75]. On the other hand, there are some cytokines, such
as interferon-γ [76], epidermal growth factor (EGF) and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) that, under certain circumstances, have dual function
by inducing not only antiapoptotic but also pro-apoptotic
signals. Forexample, GM-CSFact by phosphorylating STAT-
5, upregulating cyclin D and stimulating cell proliferation. It
canalsoupregulateprocaspase 3levelsandactivatecaspase 3,
cleave PARP, upregulate Jak-STAT-dependent pro-apoptotic
proteins like BAX, BCL2, BCL-XL, and XIAP and therefore
induce cell death [77].
Another growth promoting pathway with prognostic
value in AML is MEK/MAPK pathway, which is associated
with an apoptosis-resistance phenotype due to its anti-
apoptotic function. It is found that in primary AML cells,
MAPKisconstitutivelyactiveandpromotesleukemicgrowth
and survival. Therefore, patients with low antiapoptotic
BAX/BCL2 ratio and constitutively active MAPK pathway
have a poor prognosis, because these two factors synergis-
tically act and enhance leukemiccell survival (Figure 2)[ 78].
Summarizing the most important ﬁndings concerning
BCL2 family of genes in AML, BCL2 gene family is over-
expressed in AML and seems to play an important role
not only in disease pathogenesis, but also in resistance to
chemotherapy. BCL2 expression levels have been associated
in diﬀerent studies with FAB classiﬁcation, age, and cytoge-
netics of AML. Additionally, high BCL2 protein levels were
considered to be an adverse prognostic factor for patients
with favorable or intermediate prognosis cytogenetics and
paradoxically a favorable prognostic factor for the group of
patients with poor risk karyotype. As far as other members
of the BCL2 family are concerned, high levels of BAD and
BAX mRNA are associated with patient failure to enter CR
while increased BAD or BAD and BAX expression predicted
an adverse outcome regardless of the response to induction
chemotherapy. The correlation of BCL2 family members
with other proteins that inﬂuence their levels of expression,
such as (PKC), AXL, cytokines, or MEK/MAPK pathway, is
also interesting.
5.BCL2FamilyofGenesand CLL
B-cell Chronic Lymphocytic Leukemia (CLL) is character-
ized by the accumulation of malignant clonal CD5+ CD23+
B cells.
The most common chromosomal abnormalities in CLL
are 13 (13q14) and inversion t(11; 14)(q13; q32). Exertions
at long arm of chromosome 18 (18q21) (q32) lead to BCL2
oncogeneactivation, while theinversiont(14;19)(q32q13.1)
activates the BCL-3 oncogene [79].
Malignant CLL B cells overexpress BCL2. Until 2005 no
mechanism had been discovered to explain BCL2 deregula-
tion in CLL, with the exception of <5% of cases in which
the BCL2 gene is juxtaposed to Ig loci. Interestingly, over
the last few years, the importance of microRNAs (miRNAs)
came to the frontline. These are short noncoding RNAs of
≈19–24nt, that regulate gene expression by imperfect base
pairing with complementary sequences located mainly, but
not exclusively, in the 3  UTRs of target mRNAs. miRNAs
represent one of the major regulatory gene families in eukar-
yoticcellsbyinducingtranslational repression and transcript
degradation. The miR-15a and miR-16-1 are located in a
cluster at 13q14.3, a genomic region which is frequently
deleted in CLL. Deletions and translocations involving
these two miRNAs, as well as their downregulation, were
found in 65% of B cells in CLL patients. Cimmino et al.
demonstratedin2005thatmiR-15aandmiR-16-1expression
is inversely related to BCL2 expression in CLL and that both
miRNAs negatively regulate BCL2 at a posttranscriptional
level.Therefore, miR-15a and miR-16-1 are natural antisense
BCL2 interactors that could be used for therapy of BCL2
overexpressing tumors [80, 81].
Furthermore, various studies have focused onthe impact
of single nuclueotide polymorphisms (SNPs) of the BCL2
family genes in CLL. The polymorphism 938C > Aw i t h i na n
inhibitory region of the BCL2 promoter has been reported to
regulate BCL2 protein expression and to be associated with
adverse prognostic features in CLL (shorter overall survival,
time to ﬁrst treatment, disease stage at diagnosis and ZAP-70
status) [82]. Nevertheless, more recent studies have not con-
ﬁrmed the association of this SNP with BCL2 protein levels
or with any clinical or laboratory parameters [83]. Concern-
ing the other genes of BCL2 family, studies about the prog-
nostic role of the polymorphism G(-248)A in the promoter
region of the BAX gene are contradictive [84, 85], whereas
an SNP in the MCL-1 promoter region has been shown to
characterize CLL patients at high risk of relapse [86].
Finally, the role of epigenetic alterations is under inves-
tigation in CLL. In the majority of patients, the promoter
region forBCL2 ishypomethylated, which may contributeto
increased transcription and BCL2 protein expression in CLL
[87].
Despite the ﬁndings from in vitro assays, not all clinical
studies have identiﬁed an association between BCL2 family
members expression and patients’ outcome in B-CLL. There
are several studies showing no correlation between BCL2
protein expression and clinical features like age, sex, Rai
stage, platelet count, Hb concentration, and lymph node
involvement [88, 89] or with disease prognosis [90–92].
However, Faderl et al. [93] used a large sample of patients
(230) and RIA as method for protein detection and found
an association between BCL2, cyclin D1, FAS, PCNA, ATM
and patients’ survival. They also suggested that BCL2 is the
mostimportantproteininpredictingsurvivalamongstudied8 Advances in Hematology
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Figure 2: Cellular signalingpathways that control normal hematopoiesis and apoptosis. Molecules participating in these pathways could be
used as therapy targets in leukemias. Jak/Stat pathway is very important in leukemias, since disorders of its function lead to malignancies,
for example, chromosomaltranslocation TEL-Jak2. It participates in apoptosis regulation with various ways, for instance some Stats (2 and
3) are the mediators of the antiapoptotic eﬀects of cytokines, like IL-6 and IL-2. RTKs are membrane-bound enzymes that phosphorylate
and activate several signaling proteins. Example of this receptor is the FLT3R and mutations of the FLT3 gene have been reported in some
cases of AML. Other molecules like ERKs and Akt are involved in apoptosis through suppressing bad mediated apoptosis. Jak: Janus kinase.
STAT: signal transducer and activator of transcription. MEKs: MAPK kinases. MAPK: mitogen-activated protein kinase. ERKs: extracellular
signal-regulated kinases. RTK: receptor tyrosine kinase. PKC: protein kinase C. FLT3R: FMS-like tyrosine kinase 3 receptor. Akt: protein
kinase B (PKB). PIK3: phosphatidylinositol 3-kinase. IkB: inhibitor of nuclear factor kB. NF-κB :n u c l e a rf a c t o rk B .
proteins, since marked elevationof BCL2was linked to worst
outcome. Another assay [89] showed elevated expression
o fB C L 2 ,M C L - 1 ,B A G- 1 ,B A X ,B A K ,a n dc a s p a s e3i n
contrast to absence of BCL-XL and BAD expression in
cells from 58 patients with CLL. This study also indicated
that higher levels of MCL-1 were associated with resistance
to chemotherapy; higher levels of BAG-1 correlated with
marginal failure to achieve complete remission; and high
levels of BCL2 expression and a high BCL2/BAX ratio were
associated with elevated WBC. Moreover, a study by Faria
et al. that evaluated BCL2 protein levels before and after
treatment with ﬂudarabine indicated increased MCL1 and
BAG-1 expression in ﬂudarabine-resistant cells. Therefore, it
could be assumed that BAG-1 expression might identify CLL
patients who will need treatment earlier [94].
BCL2 family members have also been linked to resistance
to chemotherapy in CLL. More speciﬁcally, BFL1 mRNA
levels were inversely correlated with the apoptotic response
to in vitro ﬂudarabine treatment of B-CLL cells [95, 96]. In
addition, an in vitro study of Pepper et al. [84]r e g a r d i n g
resistance ofCLL cells to chlorambuciltreatment linked high
levels of BCL2 and low levels of BAX protein expression
to chemoresistance. It was observed that cells undergoing
apoptosis demonstrated a remarkable elevation of BAX
protein. Therefore, BAX was suggested as a critical protein
in determining apoptosis in leukemic cells [91, 97]. Beyond
BAX protein, MCL-1 and BAG-1 seem to be very important
in apoptosis resistance. MCL-1 is associated with dismal
prognosis [97], whereas BAG-1 protein is a very important
protein involved in apoptosis resistance, since its expression
is very high in viable cells after ﬂudarabine incubation
[94].
The relationship between BCL2 and other proteins in
CLL is also interesting. BCL2 and p53 expression seem
to be inversely related. There are indications that P53
protein overexpression downregulates BCL2 expression in
a subgroup of B-CLL patients, but this assumption needs
further investigation [98]. Another interesting point is that
BCL2is oftenoverexpressedearly inthecourseofthedisease,
whereas P53 is found in advanced stages [99]. However, P53
mRNAexpression issimilar between B-CLLcellsandnormal
cells, while P53 overexpression is considered the result of
posttranscriptional modiﬁcation [91].
As far as the relationship of BCL2 and cytokines is con-
cerned, interleukin-4 and interferon-γ are found to protect
CLL cells from apoptosis, since high levels of IL-1 are
associated with low cellular expression of BCL2 protein
[100]. NF-κB is also found to inhibit apoptosis. NF-κBi sa
dimeric nuclear transcription factor. CLL cells exhibit high
levels of NF-κB compared to normal cells [101], and in
vitro death of B-CLL cells is accompanied with the loss of
NF-κB and PI3K/AKT activities [102]. Moreover, speciﬁc
inhibition of Akt induced extensive apoptosis of CLL cells,
which wasassociatedwithbotharapidlossofMCL1throughAdvances in Hematology 9
proteasomal degradation and increased expression of p53.
CLL clones consistently contain activated Akt which plays
a pivotal role in maintaining cell survival. Inhibition of the
Akt pathway may be of potential value as a novel thera-
peutic strategy in the disease [103]. These examples show
that the interaction of apoptosis proteins with factors like
cytokinesortranscription factorsinvolvedinpathogenesisof
leukemiasis important forthe understanding ofthe complex
biology of these malignancies.
To summarize the most important ﬁndings concerning
the role of BCL2 family in CLL, we should highlight that
malignant CLL B cells overexpress BCL2, possibly through
downregulation of miR-15a and miR-16-1. These are located
in a genomic region which is frequentlydeleted in CLL. miR-
15a and miR-16-1 expression is inversely related to BCL2
expression in CLL and both miRNAs negatively regulate
BCL2 at a posttranscriptional level. The role of epigenetic
alterations is also under investigation in CLL. In the majority
ofpatients,thepromoterregionforBCL2ishypomethylated,
which may contribute to increased transcription and BCL2
protein expression. Important ﬁndings of other studies
includealinkofmarkedelevationofBCL2toworstoutcome,
association of higher levels of MCL-1 with resistance to
chemotherapy and association of higher levels of BAG-
1 with failure to achieve complete remission. Moreover,
BCL2 family members have been linked to resistance to
chemotherapy of CLL patients (Table 1).
6.BCL2Gene Familyand CML
BCR/ABLaﬀectsa number of molecularpathways, including
apoptosis. Dysregulation of the expression of BCL2 protein
seems to play a role in disease progression as shown in
mouse models. It is overexpressed in CML cells and acts
synergistically with BCR/ABL in inducing blast crisis. BCL2
is more important than c-MYC or RAS oncoproteins in the
transformation of chronic to blastic phase [104]. In vivo
studies showed that BCL2 expression is restricted to the
lymphocyte and blast subpopulation cells at the chronic
phase, whereas it is higher in the accelerated and the blastic
phase. However, other in vivo studies show that c-MYC is
more important than BCL2 protein in disease progression
since (a) it is expressed in more immature cells, (b) its
unregulated expression can inhibit myeloid diﬀerentiation,
and (c) its levels are increased in the peripheral blood
blast cell subpopulation in the accelerated and blastic phase
[105, 106]. These studies also suggest that the expression
of apoptosis oncoproteins such as BCL2, BAX, FAS and
caspase-3 is not associated with the three diﬀerent phases
of CML, since no phase-related predominance of their levels
was found.
BCR/ABL activates several signaling pathways, such as
PIK3, STAT, Ras, and NF-κβ which inﬂuence the expression
of members of the BCL2 protein family. There are several
examples of this: AKT is a serine/threonine kinase which
regulates survival signals in response to several internal and
external signals. It becomes activated through the PIK-3
signaling pathwayand itsrolefocuses oninhibiting celldeath
by two ways: the ﬁrst is the inactivation of pro-apoptotic
proteins like BAX or caspase-9, and the second is the inacti-
vation of NF-κβ and eventually BCL-XL. Another example is
STAT proteins, which are cytoplasmic proteins activated by
phosphorylation after recruitment to an activated receptor
complex. When active STAT proteins translocate to the
nucleus, they bind to speciﬁc DNA response elements and
induce the expression of STAT-regulated genes. The latter
play an important role in haemopoiesis and in heamopoietic
cell function, such as in Th1 or Th2 response in lymphocyte
function. STAT 1, 3, and 5 control cell cycle and apoptosis
and STAT 5 is found constitutively active in CML patients
[107]. The fusion BCR/ABL tyrosine kinase activates the
PIK-3/AKT pathway and the result is either phosphorylation
of BAD protein at its serine residues, or enhanced expression
of BCL-XL protein. Overexpression of BCL-XL can be
accomplished through the activation of the STAT-5 protein.
B A Da n dB C L - X La r ec o n s i d e r e dt ob et h em o s ti m p o r t a n t
regulators of apoptosis in CML [108, 109].
It has also been shown that high levels of BCR/ABL
expression are responsible for the prevention of the early
translocation of the pro-apoptotic proteins BAD and BAX
from the cytosol to the mitochondrion following a cytotoxic
signal, explaining the resistance of cells that express high
BCR/ABL levels to cytotoxic drugs [110].
Another member of the BCL2 superfamily, the BH3-only
pro-apoptotic protein BIM is considered to be an important
target in CML cells, as its downregulation is associated to the
survival of leukemic cells. It is shown in mouse models that
BIM is an essential cytokine-dependent regulator of normal
haemopoiesis [111]. BCR/ABL tyrosine kinase reverses the
induction of BIM mRNA caused by cytokine deprivation in
hematopoietic progenitor cells, and it also down-regulates
BIM expression in human CML cell lines. Therefore BIM
is considered to be an important downstream target in
CML cells that express BCR/ABL. The most likely pathway
involved in BIM mRNA down-regulation by BCR/ABL is
considered to be PIK-3 pathway [112].
Antiapoptotic protein MCL-1 is reported to be another
interesting target in CML, since BCR/ABL expressing cells
show higher expression of MCL-1 mRNA and MCL-1
protein, and the use of BCR/ABL inhibitor imatinib re-
sults in the decrease of MCL-1 expression in CML cell lines
[113].
In summary, in CML BCR/ABL is the key regulating
mechanism in disease pathogenesis and aﬀects many signal-
ing pathways including apoptosis. Nevertheless, BCL2 family
proteins do not seem to play a determining role in CML.
7.BCL2 FamilyProteinsand
LeukemiaTreatment
Since BCL2 family proteins are pivotal regulators of apop-
totic cell death and given their deregulation in acute and
chronic leukemias, the concept of manipulating their func-
tion towards enhancing their antitumor eﬀects seems a rea-
sonable strategy in the design of antileukemic therapeutic
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Impaired apoptosis reated to overexpression of BCL2
protein, which is observed in approximately 76% of patients
with CLL, is implicated in the resistance to chemotherapy.
BCL2 antisense oligonucleotides like oblimersen are used in
order to downregulate BCL2 oncoprotein in several hema-
topoietic malignancies, including CLL, multiple myeloma
and non-Hodgkin lymphoma [114–116]. In order to achieve
better clinical results, these agents are used in combination
with traditional drugs like ﬂudarabine or cyclophosphamide
and monoclonal antibodies like rituximab in several clinical
trials. While the combination of chemotherapeutic agents
(ﬂudarabine, cyclophosphamide and rituximab) has good
results in patients with CLL [117], the addition of BCL2
antisense oligonucleotides appears promising [118].
Oblimersen has also been administered during induc-
tion and consolidation treatment in untreated elderly AML
patients. After 72-hour oblimersen infusion, Bcl-2/ABL
mRNA copies were decreased compared with baseline in
patients that achieved CR, whereas it was increased in
nonresponders. Changes in Bcl-2 protein showed a similar
trend. The degree of Bcl-2 downregulation may correlate
with the response to therapy [119]. Another study demon-
strated that oblimersen can also be administered safely with
FLAG chemotherapy, downregulating its target, Bcl-2, in
previously untreated high-risk AML patients (i.e., age at
least 60 years) [120, 121]. Furthermore, expression levels of
BCL2 and BCL2L12 were found to be signiﬁcantly altered
during apoptosis induced by widely used chemotherapeutic
drugs in human leukemia cells, supporting their usefulness
as biomarkers to predict response to therapy [9, 14, 122–
128].
Studies investigating BCL2 family inhibitors, such as
ABT-737 and ABT-263, in ALL are really interesting. ABT-
737 is a pan-BCL2 inhibitor that has a wide range of single
agent activity against ALL cell lines. Furthermore, ABT-737
has been shown to enhance the activity of vincristine, L-
Asparaginase and dexamethasone against ALL cells. On the
other hand, ABT-263 is a potent, orally bioavailable BAD-
like BH3 mimetic that induces complete tumor regressions
in xenograft models of ALL. A relationship between MCL1
expression and resistance to ABT-737 has been reported,
which is abolished with the use of a synthetic cytotoxic
retinoid, N-(4-hydroxyphenyl) retinamide, that phosphory-
lates and inhibits MCL1 [129–132].
Interestingly, CLL cells were previously reported to be
highly sensitive to BCL2 inhibition and treatment with ABT-
737. Moreover, recent data support that, although struc-
turally similar and exhibiting similar binding aﬃnities to
antiapoptotic BCL2 family proteins, ABT-263 is less potent
than ABT-737 in inducing apoptosis in CLL cells. Further-
more, binding of ABT-263 to albumin seems to markedly in-
crease the concentration of drug required to induce apop-
tosis and clear CLL cells from the blood in vivo [133–
138].
The use of BCL2 inhibitors in the treatment of leukemias
is promising, either alone or in combination with classical
treatments. Given the fact that therapeutic interventions
in leukemias are often not adequate nor successful, new
therapeutic plans are more than welcome.
8.Conclusions
BCL2 protein family plays an important role in regulating
the cellular program of apoptosis. Normal cellular home-
ostasis appears to be dependent on the balance between
pro- and antiapoptotic members of BCL2 family. BCL2 is
overexpressed in almost all types and subtypes of leukemia,
indicating the importance of this molecule in disease patho-
genesisandevolution.BCL2isthemostwellstudiedmember
of the family, but evidence shows that other BCL2 related
family proteins like BAX and MCL-1 are important as well.
More speciﬁcally, MCL-1 is related to almost all leukemias
that show resistance to chemotherapy and bad prognosis.
Expression levels of BCL2 and BCL2L12 were altered during
apoptosis induced by widely used chemotherapeutic drugs
in human leukemia cells. These molecules may not be used
as disease markers in most cases, but their importance lies
in (a) explaining drug chemoresistance and (b) in the eﬀort
to design new agents with a greater speciﬁcity. Further
research should focus on the role of BCL2 family members
in leukemogenesis. It is clear that clinical studies are only
beginning to assess the expression of BCL2 family members.
Further research is more than valuable in the understanding
of the importance of this gene family in leukemias.
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